Hydrochlorothiazide

Generic Name: Hydrochlorothiazide

Brand Names: Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac

Drug Type: Small Molecule

Chemical Formula: C_₇H_₈ClN_₃O_₄S_₂

CAS Number: 58-93-5

Unique Ingredient Identifier: 0J48LPH2TH

Background: Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.

Hydrochlorothiazide was granted FDA approval on 12 February 1959.

Indication: Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.

Associated Conditions: Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Hydrochlorothiazide

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 489

Registration Number: NCT02177422

Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBR 277 SE and HCTZ
Drug: BIBR 277 SE
Drug: HCTZ

First Posted Date: 2014-06-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02176512

Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: Medium dose of Micardis®
Drug: Low dose of Micardis®
Drug: High dose of Micardis®
Drug: Hydrochlorothiazide

First Posted Date: 2014-06-26

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1039

Registration Number: NCT02175355

Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan
Drug: Losartan
Drug: Hydrochlorothiazide

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 363

Registration Number: NCT02172586

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

Phase 2

Completed

Conditions: Grade I or II Essential Hypertension

Interventions: Drug: TAK-536CCB
Drug: TAK-536CCB + Hydrochlorothiazide
Drug: Hydrochlorothiazide

First Posted Date: 2014-02-26

Last Posted Date: 2014-02-26

Lead Sponsor: Takeda

Target Recruit Count: 353

Registration Number: NCT02072330

Vascular Dysfunction in Human Obesity Hypertension

Phase 2

Terminated

Conditions: Obesity
Prehypertension
Hypertension

Interventions: Drug: Placebo
Drug: Clonidine
Drug: Hydrochlorothiazide

First Posted Date: 2013-11-14

Last Posted Date: 2023-04-14

Lead Sponsor: Gary L. Pierce

Target Recruit Count: 33

Registration Number: NCT01983462

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States

Add-on to Micamlo BP Trial

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan + amlodipine
Drug: Placebo
Drug: hydrochlorothiazide

First Posted Date: 2013-11-03

Last Posted Date: 2016-11-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 309

Registration Number: NCT01975246

Locations: 🇯🇵
1348.1.022 Boehringer Ingelheim Investigational Site, Mihama-ku, Chiba, Chiba, Japan
🇯🇵
1348.1.004 Boehringer Ingelheim Investigational Site, Miyagino-ku, Sendai, Miyagi, Japan
🇯🇵
1348.1.025 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan

and more 27 locations